This is highlighted by the severe outcomes observed in IBD patients in clinical trials with the anti-IL-17A drug secukinumab, which resulted in intestinal barrier hyperpermeability and exacerbation of disease (15). The gene discussed is IL17A; the disease is inflammatory bowel disease.